vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Savers Value Village, Inc. (SVV). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $426.9M, roughly 1.4× Savers Value Village, Inc.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -3.3%, a 44.1% gap on every dollar of revenue. On growth, Savers Value Village, Inc. posted the faster year-over-year revenue change (8.1% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $-6.3M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 4.3%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Value Village Stores, Inc. was a Midwestern United States chain of retail stores aimed at the discount department-store market. Henry Horney, formerly of F.W. Woolworth Company founded a small, regional chain of discount stores located in the two states of Wisconsin and Illinois that opened in 1961 and operated into 1989. Horney also had a real estate company and often built small shopping malls adjoining the discount stores. The chain had no relation to the Savers Value Village chain of thri...
EXEL vs SVV — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $426.9M |
| Net Profit | $244.5M | $-14.0M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | 8.5% |
| Net Margin | 40.8% | -3.3% |
| Revenue YoY | 5.6% | 8.1% |
| Net Profit YoY | 74.8% | -164.6% |
| EPS (diluted) | $0.89 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | — | ||
| Q3 25 | $568.3M | $426.9M | ||
| Q2 25 | $555.4M | $417.2M | ||
| Q1 25 | $566.8M | $370.1M | ||
| Q4 24 | — | $402.0M | ||
| Q3 24 | $539.5M | $394.8M | ||
| Q2 24 | $637.2M | $386.7M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | — | ||
| Q3 25 | $184.8M | $-14.0M | ||
| Q2 25 | $159.6M | $18.9M | ||
| Q1 25 | $139.9M | $-4.7M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | $118.0M | $21.7M | ||
| Q2 24 | $226.1M | $9.7M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | 25.6% | ||
| Q2 24 | 97.2% | 26.6% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | — | ||
| Q3 25 | 37.6% | 8.5% | ||
| Q2 25 | 33.6% | 8.2% | ||
| Q1 25 | 28.8% | 2.8% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | 25.2% | 12.3% | ||
| Q2 24 | 43.3% | 8.3% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | — | ||
| Q3 25 | 32.5% | -3.3% | ||
| Q2 25 | 28.7% | 4.5% | ||
| Q1 25 | 24.7% | -1.3% | ||
| Q4 24 | — | -0.5% | ||
| Q3 24 | 21.9% | 5.5% | ||
| Q2 24 | 35.5% | 2.5% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | — | ||
| Q3 25 | $0.65 | $-0.09 | ||
| Q2 25 | $0.55 | $0.12 | ||
| Q1 25 | $0.47 | $-0.03 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | $0.40 | $0.13 | ||
| Q2 24 | $0.77 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $63.5M |
| Total DebtLower is stronger | — | $750.0M |
| Stockholders' EquityBook value | $2.2B | $414.6M |
| Total Assets | $2.8B | $2.0B |
| Debt / EquityLower = less leverage | — | 1.81× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | — | ||
| Q3 25 | $791.1M | $63.5M | ||
| Q2 25 | $1.0B | $70.5M | ||
| Q1 25 | $1.1B | $73.0M | ||
| Q4 24 | — | $150.0M | ||
| Q3 24 | $1.2B | $137.7M | ||
| Q2 24 | $1.0B | $160.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $750.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.0B | $414.6M | ||
| Q2 25 | $2.1B | $423.5M | ||
| Q1 25 | $2.2B | $413.8M | ||
| Q4 24 | — | $421.7M | ||
| Q3 24 | $2.3B | $432.9M | ||
| Q2 24 | $2.1B | $419.5M |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.7B | $2.0B | ||
| Q2 25 | $2.8B | $1.9B | ||
| Q1 25 | $2.9B | $1.9B | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | $3.0B | $1.9B | ||
| Q2 24 | $2.8B | $1.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.81× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $21.6M |
| Free Cash FlowOCF − Capex | $332.4M | $-6.3M |
| FCF MarginFCF / Revenue | 55.5% | -1.5% |
| Capex IntensityCapex / Revenue | 0.2% | 6.5% |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $25.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | — | ||
| Q3 25 | $49.0M | $21.6M | ||
| Q2 25 | $211.4M | $54.4M | ||
| Q1 25 | $240.3M | $419.0K | ||
| Q4 24 | — | $55.8M | ||
| Q3 24 | $271.3M | $23.9M | ||
| Q2 24 | $119.5M | $60.4M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | — | ||
| Q3 25 | $46.2M | $-6.3M | ||
| Q2 25 | $208.5M | $21.9M | ||
| Q1 25 | $236.3M | $-20.2M | ||
| Q4 24 | — | $30.1M | ||
| Q3 24 | $263.1M | $-3.0M | ||
| Q2 24 | $113.0M | $29.6M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | — | ||
| Q3 25 | 8.1% | -1.5% | ||
| Q2 25 | 37.5% | 5.2% | ||
| Q1 25 | 41.7% | -5.4% | ||
| Q4 24 | — | 7.5% | ||
| Q3 24 | 48.8% | -0.8% | ||
| Q2 24 | 17.7% | 7.6% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.5% | 6.5% | ||
| Q2 25 | 0.5% | 7.8% | ||
| Q1 25 | 0.7% | 5.6% | ||
| Q4 24 | — | 6.4% | ||
| Q3 24 | 1.5% | 6.8% | ||
| Q2 24 | 1.0% | 8.0% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | — | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 1.32× | 2.88× | ||
| Q1 25 | 1.72× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.30× | 1.10× | ||
| Q2 24 | 0.53× | 6.22× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
SVV
| Sales Channel Directly To Consumer | $408.3M | 96% |
| Sales Channel Through Intermediary | $18.6M | 4% |
